Bringing Targeted Therapies
to Patients in Need
We discover and target the hidden genetic vulnerabilities of the two thirds of cancers driven by loss-of-function mutations. By using our novel OncoSLX platform™ to retarget de-risked clinical-stage drugs, we accelerate drug development, reduce translational risk and deliver better patient outcomes.
Our Focus
Two-thirds of cancers are driven by genetic mutations that inactivate critical tumor-suppressor genes. These loss-of-function mutations also create vulnerabilities that can be pharmacologically targeted to selectively kill cancer cells. Our focus is on systematically identifying these novel pharmacogenetic relationships for drugs that are already de-risked in the clinic and then developing them as precision therapeutics.
Our Approach
Our proprietary OncoSLX platform enables a unique pharmacologically based approach that uses drugs, rather than genetic knockouts typical in synthetic lethality screening, to identify vulnerabilities induced by loss-of-function mutations. Because small molecules can modulate diverse biological mechanisms beyond a simple gene knockout, our screens reveal a much broader spectrum of actionable vulnerabilities than conventional synthetic-lethality methods can uncover.
Our Pipeline
Our lead product candidate, LFB190, is a potentially first-in-class and best-in-class BET inhibitor targeting cancers driven by EP300 loss of function mutations – an area of significant unmet clinical need. Our platform has also identified a potentially practice changing approach to treating PIK3CA mutant cancers and several other novel, high potential genetically targeted therapies.
